Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and ...

China: A recent retrospective cohort study has highlighted the significant role of pulmonary infections in influencing ...

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

Currently, there is no feline vaccine for the hepatitis B virus, and the hepatitis B vaccine for humans is highly toxic to ...

Chronic hepatitis B (CHB) is currently estimated to affect over 250 million people worldwide, and tenofovir disoproxil fumarate (TDF) is currently the most widely used antiviral agent for CHB ...

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...